← Product Code [GAM](/submissions/SU/subpart-e%E2%80%94surgical-devices/GAM) · K972566 # DEXON VIOLET (K972566) _Davis & Geck, Inc. · GAM · Aug 14, 1997 · General, Plastic Surgery · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/GAM/K972566 ## Device Facts - **Applicant:** Davis & Geck, Inc. - **Product Code:** [GAM](/submissions/SU/subpart-e%E2%80%94surgical-devices/GAM.md) - **Decision Date:** Aug 14, 1997 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 878.4493 - **Device Class:** Class 2 - **Review Panel:** General, Plastic Surgery - **Attributes:** Therapeutic ## Intended Use The Dexon® Violet Polyglycolic Acid Suture Surgical Suture is indicated for use in 1. general soft tissue approximation and/or ligation, including use in ophthalmic procedures, but not for use in cardiovascular and neurological procedures. ## Device Story DEXON® Violet Polyglycolic Acid Suture is a synthetic, braided, absorbable surgical suture composed of polyglycolic acid homopolymer, coated with Polycaprolate (copolymer of glycolide and epsilon-caprolactone). Used by surgeons for soft tissue approximation and ligation. Device elicits minimal acute inflammatory tissue reaction; undergoes gradual encapsulation by fibrous connective tissue. Tensile strength loss and absorption occur via hydrolysis, degrading into glycolic acid for metabolic absorption. Available in various lengths, diameters, and quantities, with or without surgical needles. Sterile, inert, noncollagenous, nonantigenic, and nonpyrogenic. ## Clinical Evidence Bench testing only. Testing performed in accordance with USP guidelines included: cytotoxicity, pyrogenicity, hemolysis, sensitization, mutagenicity, acute systemic toxicity, intracutaneous, intramuscular implant, mammalian mutagenicity, 6-month ambient storage stability, and in-vivo strength retention. ## Technological Characteristics Synthetic braided absorbable suture; homopolymer of glycolic acid coated with Polycaprolate (glycolide/epsilon-caprolactone copolymer). Sterile, noncollagenous, nonantigenic, nonpyrogenic. Dimensions vary by length and diameter. No electronic components or software. ## Regulatory Identification An absorbable poly(glycolide/l-lactide) surgical suture (PGL suture) is an absorbable sterile, flexible strand as prepared and synthesized from homopolymers of glycolide and copolymers made from 90 percent glycolide and 10 percent l-lactide, and is indicated for use in soft tissue approximation. A PGL suture meets United States Pharmacopeia (U.S.P.) requirements as described in the U.S.P. “Monograph for Absorbable Surgical Sutures;” it may be monofilament or multifilament (braided) in form; it may be uncoated or coated; and it may be undyed or dyed with an FDA-approved color additive. Also, the suture may be provided with or without a standard needle attached. ## Special Controls *Classification.* Class II (special controls). The special control for this device is FDA's “Class II Special Controls Guidance Document: Surgical Sutures; Guidance for Industry and FDA.” See § 878.1(e) for the availability of this guidance document. ## Predicate Devices - DEXON® Polyglycolic Acid Suture ([K951352](/device/K951352.md)) - Dexon II Absorbable Suture ([K900198](/device/K900198.md)) - Polysorb Violet Suture Braided (Polyglactin 910) Suture ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ ## 510k Summary of Safety and Effectiveness ## DEXON® Violet Polyglycolic Acid Suture K972566 - Submitted by: Sherwood-Davis & Geck 444 McDonnell Blvd. Hazelwood, MO 63042-2516 AUG 1 4 1997 Contact: Vanada Johnson Regulatory Affairs Specialist Date of Summary: July 8, 1997 DEXON® Violet Polyglycolic Acid Suture is a synthetic absorbable sterile surgical suture composed of homopolymers of glycolic acid and is a class II device, per 21 CFR Section 878.4493. Procode: 73GAM. DEXON® Violet is a braided synthetic absorbable surgical suture composed of homopolymer of glycolic acid and coated with Polycaprolate, a copolymer of glycolide and epsilon-caprolactone and is indicated for use as an absorbable suture in general soft tissue approximation and/or ligation, including use in ophthalmic procedures, but not for use in cardiovascular or neural tissue. The DEXON® Violet Polyglycolic Acid Suture is an addition to the DEXON® family of Polyglycolic Acid Sutures and is sterile, inert, noncollagenous, nonantigenic and nonpyrogenic. DEXON Violet Polyglycolic Acid Sutures are available in various lengths, diameters and quantities with and without surgical needles. The DEXON® Violet Polyglycolic Acid Suture elicits a minimal acute inflammatory reaction in tissues, followed by gradual encapsulation of the suture by fibrous connective tissue. Progressive loss of tensile strength and eventual absorption of the polyglycolic Acid sutures occur by means of hydrolysis, where the polymer degrades to glycolic acid and is subsequently absorbed and metabolized by the body. The following battery of tests were performed in accordance to, and satisfied USP guidlines - Cytotoxicity, Pyrogenicity, Hemolysis, Sensitization, Mutagenicity, Acute Systemic Toxicity, Intracutaneous, Intramuscular Implant, Mammalian Mutagenicity, 6-Month Ambient Storage Stability and In-Vivo Strength Retention. Under Section 514 of the FD&C Act, performance standards have not been promulgated for this device at this time. Sherwood-Davis & Geck considers DEXON® Violet Polyglycolic Acid Suture substantially equivalent to the predicate devices, the DEXON® Polyglycolic Acid Suture covered under 510(k) K951352, Dexon II Absorbable Suture covered under 510(k) K900198, Vicryl . . . . . and Polysorb Violet Suture Braided (Polyglactin 910) Suture covered : : {1}------------------------------------------------ Image /page/1/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with three stripes forming its body and two wavy lines below, representing water. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular fashion around the eagle. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Ms. Vanada Johnson Regulatory Affairs Specialist -Sherwood Davis & Geck ---444 McDonnell Boulevard Hazelwood. Missouri 63042-2516 AUG 1 4 1997 Re: K972566 Dexon® Violet Polyglycolic Acid Suture Regulatory Class: II Dated: July 8, 1997 Received: July 9, 1997 Dear Ms. Johnson: We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices that were regulated as transitional devices and that have been reclassified into class II. Notice of this reclassification was published in the Federal Register on Wednesday, September 18, 1991 (Vol. 56, No. 18, Pages 47150 and 47151). A copy of this Federal Register can be obtained by calling the Division of Small Manufacturers Assistance (DSMA) at (800) 638-2041 or (301) 443-6597. You may, therefore, market the device, subject to the general controls provisions of the Federal Food, Drug, and Cosmetic Act (Act) and the following limitations: - The Dexon® Violet Polyglycolic Acid Suture Surgical Suture is indicated for use in 1. general soft tissue approximation and/or ligation, including use in ophthalmic procedures, but not for use in cardiovascular and neurological procedures. - This device may not be manufactured from any material other than homopolymers 2. and copolymers made from glycolide and/or I .- lactide Any deviation of the polymer composition or processing as described in this 510(k) notification must be submitted to FDA in a new premarket notification at least 90 days prior to implementation of the proposed changes. In addition, you must maintain documentation at your premises regarding vendor certification for raw or semiprocessed source material, all manufacturing and quality control release procedures, and validation of sterilization procedures used in the manufacture of the Dexon® Violet Polyglycolic Acid surgical suture. Any deviation of the source material or processing as described in this 510(k) notification requires submission of a new premarket notification and Food and Drug Administration (FDA) clearance prior to commercial distribution of the modified device. {2}------------------------------------------------ Page 2 - Ms. Vanada Johnson The sale, distribution and use of this device are restricted to prescription use in accordance with 21 CFR 801.109. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practices, labeling, and prohibition against misbranding and adulteration. ------------------------------------------------------------------------------------------------------------------------------------------------ Existing major regulations affecting your device can be found in the Code of Federal Regulations (CFR), Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practices (GMP) for Medical Devices: General GMP regulation (21 CFR Part 820) and that, through periodic GMP inspections, The Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control Provisions, or other Federal laws or regulations. This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits vour device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html". Sincerely yours, Celia M. Witten, Ph.D., M.D. Director Division of General and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health {3}------------------------------------------------ Page 1 of 1 | 510(k) Number (if known) | K972566 | |--------------------------|---------| |--------------------------|---------| Device Name: Sherwood-Davis & Geck DEXON® Violet Polyglycolic Acid Suture Indications for Use: The Polyglycolic Acid sutures are indicated for use as absorbable sutures in ......................................................................................... general soft tissue approximation and/or ligation, including use in ophthalmic procedures, but not for use in cardiovascular or neural tissue. ## (PLEASE DO NO WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) | | Concurrenc of CDRH, Office of Device Evaluation (ODE) | |------------------------------------------|----------------------------------------------------------------| | Prescription Use
(Per 21 CFR 801.109) |
X
| | | OR | | | Over-the-Counter Use | | (Division Sign-off) | (Division Sign-Off)
Division of General Restorative Devices | | 510(k) Number | k972866 | Sherwood-Davis & Geck DEXON® Violet Polyglycolic Acid Suture Premarket Notification --- **Source:** [https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/GAM/K972566](https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/GAM/K972566) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com